天境生物之前持有中国权益。。
同药不同命的CD38
BIIB to acquire HI-Bio for $1.15B upfront and up to $650M in potential milestone payments. HI-Bio’s lead asset, Felzartamab, is a fully human anti-CD38 monoclonal antibody that has been shown in clinical studies to selectively deplete CD38+ cells including plasma cells and NK cells.